Potassium Binders
High-yield Verified · Oct 2026Know the binders by what they release or grab: SPS gives up sodium and takes magnesium and calcium too, patiromer takes magnesium, and SZC holds on to potassium even when calcium and magnesium are present but carries sodium. Their delayed onset makes them the removal step after calcium and the shift drugs.
Nursing view → administration, monitoring and patient teaching
Compare: Potassium disorders — the drugs that cause them and the drugs that correct them →
Drugs
Mechanism
Potassium binders are non-absorbed agents that bind potassium in the lumen of the gastrointestinal tract and increase fecal potassium excretion. Less free potassium in the lumen lowers serum potassium. Sodium polystyrene sulfonate is a cation-exchange resin that releases sodium in exchange for potassium, mostly in the large intestine; its efficiency is limited and unpredictable, and it is not selective, so magnesium and calcium are also lost. Patiromer is a cation-exchange polymer with a calcium-sorbitol counterion, and it also binds magnesium in the colon. Sodium zirconium cyclosilicate is a zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium, with a high affinity for potassium even in the presence of calcium and magnesium.
Exchange in the gut lumen
None of the binders is absorbed. Each binds potassium in the lumen of the gastrointestinal tract, which lowers the free potassium in the lumen and raises fecal potassium excretion. The kidney sees the other side of this: in healthy volunteers patiromer raised fecal potassium and lowered urinary potassium excretion while serum potassium did not change. The body simply excreted less potassium in the urine.
Sodium polystyrene sulfonate (SPS) is a cation-exchange resin. As it passes along the intestine, sodium ions are partly released and replaced by potassium, mostly in the large intestine, which excretes potassium to a greater degree than the small intestine. Its efficiency is limited and unpredictably variable (commonly around 33%), and competition from other cations, especially sodium, calcium and magnesium, lowers its exchange capacity. Because it is not selective, magnesium and calcium are lost too.
Patiromer is a cation-exchange polymer with a calcium-sorbitol counterion, and it also binds magnesium in the colon. Sodium zirconium cyclosilicate (SZC) is an inorganic zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium, with a high affinity for potassium even in the presence of calcium and magnesium. SZC also causes a small, dose-dependent rise in serum bicarbonate, of unclear clinical significance.
Why the binders are the removal step
A binder lowers serum potassium only as potassium is bound in the gut and carried out, so the fall is gradual. On the labels, serum potassium fell about 1 hour after SZC was started and about 7 hours after the first patiromer dose, and kept falling over 48 hours. With SPS, effective lowering may take hours to days. The patiromer and SZC labels therefore state that neither should be used as emergency treatment for life-threatening hyperkalemia. The SPS label warns that SPS alone may not correct severe hyperkalemia quickly enough, and that other definitive measures, including dialysis, should always be considered.
When hyperkalemia changes the ECG, calcium stabilizes the cardiac membrane and insulin or a β2 agonist shifts potassium into cells first; the Electrolyte & Fluid Replacement page teaches that sequence. The binders and hemodialysis then take potassium out of the body; hemodialysis is the definitive treatment in end-stage or severe kidney disease.
The binders’ other role is chronic control. Patiromer was studied in hyperkalemic patients with chronic kidney disease on stable doses of a renin–angiotensin–aldosterone system inhibitor. When patients whose potassium had been controlled were switched to placebo, serum potassium rose by 0.72 mEq/L, against no change in those who stayed on patiromer. Potassium also rose again after patiromer or SZC was stopped in the pharmacodynamic studies.
SPS: the colon, sorbitol and necrosis
In the past, SPS was given with sorbitol to reduce the chance of constipation. Cases of intestinal necrosis, which may be fatal, and other serious GI events (bleeding, ischemic colitis, perforation) have been reported with SPS, and most of them involved sorbitol given at the same time. In 2009 the FDA warned against using SPS with sorbitol. Risk factors in many cases were prematurity, previous intestinal disease or surgery, hypovolemia, and kidney insufficiency or failure. SPS is used only in patients with normal bowel function and is stopped if constipation develops.
SPS use has fallen because of questionable efficacy and gastrointestinal complications such as colonic necrosis. It interacts with what else is in the gut. Nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate may reduce its potassium exchange and have caused systemic alkalosis. Concretions of aluminum hydroxide combined with SPS have caused intestinal obstruction.
Sodium, magnesium and gastric pH
Sodium. About a third of SPS’s sodium content is delivered to the body, and SPS can contribute to sodium overload and fluid retention. It needs caution in severe heart failure, severe hypertension and marked edema. SZC contains sodium too, and in trials edema rose with dose (4.4%, 5.9% and 16.1% across the three doses tested, against 2.4% on placebo).
Magnesium. Patiromer binds magnesium in the colon. Hypomagnesemia was reported as an adverse reaction in 5.3% of adults, and about 9% developed a serum magnesium below 1.4 mg/dL. SPS also removes magnesium and calcium, because it is not selective.
Other oral drugs. SPS and patiromer bind some oral drugs in the gut. Patiromer lowered exposure to ciprofloxacin, levothyroxine and metformin, but there was no interaction when they were taken 3 hours apart, so the labels require 3-hour spacing (6 hours for SPS with gastroparesis). SZC acts differently: it transiently raises gastric pH. Exposure to weak acids such as furosemide and atorvastatin rose, while exposure to weak bases such as dabigatran, and to tacrolimus, fell, so its label spaces other oral drugs by 2 hours.
Comparing the drugs
Three binders side by side
| Drug | What it exchanges or binds | Onset (label) | Signature risks | Oral-drug spacing |
|---|---|---|---|---|
| Sodium polystyrene sulfonate (oral or enema) | Releases sodium for potassium, mostly in the colon; not selective (magnesium, calcium lost) | Hours to days | Intestinal necrosis (mostly with sorbitol); sodium load; hypokalemia | 3 h (6 h with gastroparesis) |
| Patiromer (oral) | Cation-exchange polymer with a calcium-sorbitol counterion; also binds magnesium | About 7 h | Hypomagnesemia; constipation | 3 h |
| Sodium zirconium cyclosilicate (oral) | Captures potassium for hydrogen and sodium; high potassium affinity with calcium and magnesium present | About 1 h | Edema (sodium content); hypokalemia on hemodialysis | 2 h (raises gastric pH) |
Pharmacokinetics
- Not absorbed — patiromer, sodium zirconium cyclosilicate, sodium polystyrene sulfonate
- In animal studies patiromer was not systemically absorbed: it was excreted in the feces, and radioactivity stayed in the gastrointestinal tract. SZC is an inorganic, insoluble compound that is not metabolized by enzymes; zirconium levels in blood and urine were similar in treated and untreated patients. SPS is not absorbed systemically either. Because they are not absorbed, maternal use is not expected to result in fetal risk (patiromer) or fetal exposure (SZC).
- Onset and offset — all three
- Serum potassium fell about 1 hour after SZC was started and about 7 hours after the first patiromer dose, and kept falling over 48 hours; SPS may take hours to days. When patiromer was stopped, potassium stayed stable for 24 hours and then rose; it also rose in patients who did not continue SZC.
Uses & drug choice
- Sodium polystyrene sulfonate (Kionex) for hyperkalemia
- Patiromer (Veltassa) for hyperkalemia in adults and children 12 years and older; not for emergency treatment of life-threatening hyperkalemia, because its onset is delayed
- Sodium zirconium cyclosilicate (Lokelma) for hyperkalemia in adults; not for emergency treatment of life-threatening hyperkalemia, because its onset is delayed
Adverse effects
- Intestinal necrosis (SPS)
- Reported mostly when sorbitol was given with SPS. Risk factors were prematurity, previous intestinal disease or surgery, hypovolemia, and kidney insufficiency or failure; the risk is why SPS needs normal bowel function.
- Hypomagnesemia (patiromer; also SPS)
- Patiromer binds magnesium in the colon. SPS is not selective for potassium, so magnesium and calcium are also lost.
- Edema and sodium load (SZC, SPS)
- SZC contains sodium, and its edema rose with dose. SPS releases sodium in exchange for potassium, and about a third of its sodium reaches the body.
- Altered absorption of other oral drugs
- SPS and patiromer bind drugs in the gut. SZC raises gastric pH, which changes the absorption of drugs whose solubility depends on pH.
- Hypokalemia that the serum level underestimates (SPS)
- Intracellular potassium deficiency is not always reflected by serum potassium, so the SPS label uses the clinical condition and the ECG to decide when to stop.
- Systemic alkalosis (SPS with cation-donating antacids)
- Reported when SPS was given orally with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate; magnesium hydroxide is not given with SPS.
Toxicity & antidote
Excessive patiromer doses may cause hypokalemia, and serum potassium is restored if it occurs. SPS overdose causes hypokalemia, hypocalcemia and hypomagnesemia: irritability, confusion, delayed thought, muscle weakness and hyporeflexia that may progress to paralysis or apnea, sometimes tetany, and ECG changes or arrhythmias. Treatment corrects potassium, calcium and magnesium and removes the resin from the gut with laxatives or enemas.
Interactions
Contraindications
- Hypokalemia (SPS) — Labeled contraindication: a drug that removes potassium would make the deficit worse.
- Obstructive bowel disease (SPS) — Labeled contraindication: the resin works as it passes along the intestine, and SPS can cause intestinal necrosis and perforation.
- Oral or rectal SPS in neonates — Labeled contraindication, especially in premature infants; prematurity was a risk factor in reported intestinal necrosis.
- Hypersensitivity to polystyrene sulfonate resins (SPS) or to patiromer or its components — Labeled contraindication on each label; patiromer reactions have included lip edema.
- Life-threatening hyperkalemia needing emergency treatment use caution — Patiromer and SZC should not be used as emergency treatment because their onset is delayed; SPS alone may not correct severe hyperkalemia fast enough, so other definitive measures, including dialysis, are considered.
- Severe constipation, bowel obstruction or impaction, or abnormal post-operative bowel motility use caution — Patiromer and SZC are avoided because they may not work and may worsen the condition. SPS is used only with normal bowel function, and not after surgery until the patient has had a bowel movement.
- Severe heart failure, severe hypertension, marked edema, or proneness to fluid overload use caution — SPS needs caution and SZC needs edema monitoring, because both deliver sodium.
- Impaired gag reflex, altered consciousness or proneness to regurgitation (SPS) use caution — Raises the risk of aspirating resin particles; SPS is given upright.
High-yield
Practice questions
Q1A 70-year-old man with stage 4 chronic kidney disease who takes lisinopril has a serum potassium of 7.1 mEq/L, and his ECG shows peaked T waves and a widening QRS. The team gives IV calcium gluconate, then insulin with dextrose, and plans a potassium binder afterward.
Why is the potassium binder not the first drug given?
- A.It lowers potassium by blocking renal potassium secretion
- B.It is contraindicated in chronic kidney disease
- C.Its onset of action is delayed
- D.It works only after insulin has shifted potassium into cells
- E.It is absorbed and accumulates when kidney function is poor
Show answer
C. Its onset of action is delayed — Binders lower potassium only as it is bound in the gut and excreted, so the fall takes hours: the patiromer and SZC labels exclude emergency use for that reason, and SPS may take hours to days. They do not block renal secretion; they raise fecal potassium excretion, and urinary potassium excretion falls. They are not contraindicated in kidney disease (93% of the adults in patiromer’s trials had chronic kidney disease), they act by binding potassium in the gut rather than through a shift into cells, and none of them is absorbed.
Q2A 78-year-old woman had abdominal surgery 2 days ago and has not yet had a bowel movement. She receives sodium polystyrene sulfonate with sorbitol for a potassium of 6.0 mEq/L. Eighteen hours later she has severe abdominal pain and bloody stools.
Which complication is most likely?
- A.Hypermagnesemia
- B.Aspiration pneumonitis
- C.Systemic alkalosis
- D.Intestinal necrosis
- E.Edema from the sodium load
Show answer
D. Intestinal necrosis — Intestinal necrosis, with bleeding, ischemic colitis or perforation, has been reported with SPS, mostly when sorbitol was given at the same time, and recent intestinal surgery is a risk factor. SPS is avoided in patients who have not had a bowel movement after surgery. SPS removes magnesium (hypomagnesemia, not hypermagnesemia). Aspiration causes bronchitis or bronchopneumonia, not GI bleeding. Systemic alkalosis follows co-administration with magnesium hydroxide or aluminum carbonate, and the sodium load causes fluid retention, not bloody stools.
Q3A 63-year-old woman with diabetic kidney disease has taken patiromer for 3 months for recurrent hyperkalemia. She reports new muscle weakness. Her serum potassium is 4.6 mEq/L and her serum magnesium is 1.2 mg/dL.
Which mechanism best explains the abnormal laboratory value?
- A.Patiromer binds magnesium in the colon
- B.Patiromer raises gastric pH and blocks magnesium absorption
- C.Patiromer exchanges magnesium for sodium in the renal tubule
- D.Hyperkalemia suppresses intestinal magnesium absorption
- E.Patiromer lowers serum bicarbonate, causing renal magnesium wasting
Show answer
A. Patiromer binds magnesium in the colon — Patiromer binds magnesium in the colon, which can cause hypomagnesemia (an adverse reaction in 5.3% of adults); serum magnesium is monitored and supplemented if it falls. Raising gastric pH is SZC’s effect, not patiromer’s. Patiromer is not absorbed, so it acts in the gut lumen, not the renal tubule. Her potassium is normal, so hyperkalemia is not the cause, and the small change in serum bicarbonate on the labels is a rise, seen with SZC.
Q4A 72-year-old man with heart failure and chronic kidney disease takes furosemide. Two weeks after starting sodium zirconium cyclosilicate for hyperkalemia he has new ankle edema and a 2-kg weight gain.
Which property of the drug most likely explains this?
- A.It binds magnesium in the colon
- B.It releases calcium in exchange for potassium
- C.It lowers serum bicarbonate, causing acidosis
- D.It blocks aldosterone in the collecting duct
- E.It contains sodium
Show answer
E. It contains sodium — SZC contains sodium, and in trials edema rose with dose. Its label advises watching for edema in patients prone to fluid overload, such as those with heart failure or kidney disease, adjusting dietary sodium and increasing diuretics as needed. Binding magnesium in the colon is patiromer’s effect. SZC captures potassium in exchange for hydrogen and sodium, not calcium, and it raises serum bicarbonate slightly rather than lowering it. It is not absorbed (zirconium levels were similar in treated and untreated patients), so it cannot act on the collecting duct.
Sources
- Kionex (sodium polystyrene sulfonate) — FDA label: mechanism, contraindications, intestinal necrosis and sorbitol, delayed effect, hypokalemia, sodium load, aspiration, oral drug binding — FDA / DailyMed
- Veltassa (patiromer) — FDA label: mechanism, emergency limitation, hypomagnesemia, GI motility, 3-hour separation, onset — FDA / DailyMed
- Lokelma (sodium zirconium cyclosilicate) — FDA label: mechanism, emergency limitation, edema, hemodialysis, gastric pH and 2-hour separation, onset — FDA / DailyMed
- Sodium Polystyrene Sulfonate — place in therapy, sorbitol warning, sodium overload — StatPearls / NCBI Bookshelf
- Hyperkalemia — causes, stabilize–shift–eliminate management, place of the cation exchangers — StatPearls / NCBI Bookshelf
- The use of stems in the selection of INN (stem -mer) — World Health Organization
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.